On-Demand DCT Webinars

  1. Increase Inclusivity And Reduce Costs With A DCT Approach 12/10/2021

    In this presentation, John Reites, CEO of THREAD will provide global insights and guidance on improving participant inclusion in global clinical trials, while driving the understanding of how DCTs can reduce costs in parallel. 

  2. Best Practices For Global DCT Adoption 12/10/2021

    In this session, John Reites, CEO of THREAD shares his perspectives and best practices focused on scaled adoption of decentralized clinical trial approaches.

  3. Best Practices For Conducting Decentralized Clinical Trials In Japan 11/23/2021

    This webinar discusses decentralized clinical trials and the benefits they have proven for the clinical trial industry, specifically in Japan.

  4. What Can An Advanced Digital Platform Bring To Decentralized Clinical Trials? 10/28/2021

    In this video, Edward Triebell, Executive Director, Product Development of Digital Health, shares the key considerations around implementing technology and technological elements within clinical trials, recommendations on the best practices for integrating new systems and technologies, as well as what the future looks like when it comes to technology and decentralized trials.

  5. Enabling Diversity & Inclusion In Clinical Trials: A CRO & IRB Perspective 8/6/2021

    In the first webinar in the series, Amanda Ryan, President of G3 Life Sciences, will speak with Aman Khera, VP, Global Head of Regulatory Strategy at Worldwide Clinical Trials, and Luke Gelinas, Advarra’s IRB Chair and Senior Advisor, about their perspective on diversity in clinical trials.

  6. Advancing Decentralized Trials Using An mHealth Platform 7/14/2021

    While COVID-19 has ushered in some much-needed innovations in terms of technology solutions to power decentralized, not all solutions are created equal. When evaluating mHealth technology, for example, the integrity of data collection and data privacy are paramount. In this webinar we discuss the key considerations when making an investment in an mHealth platform.

  7. A Multi-Disciplinary Perspective On Decentralized Study Design 7/1/2021

    The biopharmaceutical industry is rapidly adopting methodologies that decentralize research by harnessing transformative data acquisition and patient engagement thus taking the research beyond the walls of the legacy study setting. To truly realize the promise of decentralized research models, a dynamic array of technological capabilities, traditional research core competencies, and innovative study design expertise is required. Join us as we explore operational challenges, technical solutions, and design considerations.

  8. Leveraging Analytics To Improve Data Quality And Increase Enrollment In Decentralized Clinical Trials 7/1/2021

    As clinical research is increasingly moving to a decentralized model, it’s critical that the patient matching and enrollment process is streamlined and data-driven to speed the clinical trial process. This webinar discusses how leveraging a data-driven approach to patient recruitment and enrollment allows sponsors of clinical research to overcome these challenges and accelerate their trial timelines.

  9. Trials And Tribulations Of Electronic Patient Consent: Removing Barriers To eConsent Adoption 6/3/2021

    After a decade of dabbling with eConsent, how can sponsors and technology providers meet the demand to bring clinical trials directly to the patient at a global scale? In this webinar, you’ll learn strategies to overcome the persistent challenges in eConsent adoption and gain the benefits promised from successful decentralized trials with remote capabilities for patients and sites.

  10. Will Patient Engagement Be A Challenge In Decentralized Trials? 4/14/2021

    In this webinar segment, Tero Laulajainen, VP and head of global clinical science and operations for UCB, and Hassan Kadhim, global head of clinical trial business capabilities, clinical innovation, and industry collaborations at Bristol-Myers Squibb discuss interactions with patients when they are not engaging with nurses and physicians in-person during visits to clinics.